SOURCES SOUGHT
70 -- Access to Data on Expenditures by Pharmaceutical Companies on Prescription Drug Promotion
- Notice Date
- 11/4/2008
- Notice Type
- Sources Sought
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services, 5630 Fishers Lane, Room 2129, Rockville, Maryland, 20857-0001
- ZIP Code
- 20857-0001
- Solicitation Number
- 1051583-1
- Response Due
- 12/15/2008
- Archive Date
- 12/30/2008
- Point of Contact
- Linda Giles,, Phone: 301-827-7048, Ted Weitzman,, Phone: 301-827-7178
- E-Mail Address
-
linda.alexander-giles@fda.hhs.gov, ted.weitzman@fda.hhs.gov
- Small Business Set-Aside
- Total Small Business
- Description
- This is a SOURCES SOUGHT NOTICE to determine the availability and capability of qualified small businesses that can provide access to current and historical data for analysis and forecasting of trends in expenditures by pharmaceutical companies associated with promotional and advertising strategies of prescription drugs and biologics. The ability of FDA to respond expeditiously to questions relating to the oversight of drug advertising and promotion and its impact on regulatory policy is of paramount importance to the overall public health of the Nation. The prescription drug promotion data shall include, but is not limited to, expenditures by pharmaceutical companies for promotional contacts to office- and hospital-based physicians; product samples to office-based physicians; product advertising in medical journals; and direct-to-consumer (DTC) advertising. Access to these data enhances and accelerates the pace of FDA's regulatory decision-making process and FDA’s responses to requests from Health and Human Services (HHS) and Congress. The contractor shall provide the following: 1) Prescription Drug Promotion Data. Data should describe national estimates of expenditures by pharmaceutical companies including national estimates of product sampling and promotional expenditure data as well as the content and message of pharmaceutical detailing and advertising campaigns. The promotion-specific basic data elements shall include (but are not limited to): monthly summary of promotional dollar expenditures for manufactures and pharmaceutical products; physician office-based promotional expenses (includes cost of promotional contacts, on-site educational presentations, telephone calls, and service visits); hospital-based promotional expenses (included cost of promotional contacts to hospital-based physicians and pharmacists, on-site educational presentations, and drug fairs); professional journal advertising (including medical, dental, hospital, and drug trade journals); retail value of samples provided to office-based physicians; retail value of samples provided to hospitals (desired, but not required); DTC advertising (e.g., TV, radio, newspaper, magazine, and outdoor advertising); additional DTC media (e.g., mailings to consumers such as coupons and cost of internet advertising) (desired, but not required); and expenses for promotional presentations (e.g., dinner meetings, exhibit booths at conferences, etc.) (desired, but not required). The basic data elements for the office-based and hospital-based contact reports shall include (but are not limited to): information to include the total contacts to office-based physicians and hospital-based physicians and pharmacists, including specialty physicians; the details of the message provided to physicians (first time detail, use of product, and product message discussed); the ability to search by key phrase in message provided to physician; the ability to search by geographic area of the country for specific messaging; the details of number of minutes spent on calls (desired, but not required); and dollars spent by specialty on contacts (desired, but not required). The basic data elements for manufacturer and pharmaceutical product sampling reports shall include (but are not limited to): information to include form, strength, and volume of product samples provided to office-based physicians; hospital sampling information (desired, but not required); and information to include how the sample was provided (e.g., via in-person presentation, left during service visit, sent by mail) (desired, but not required). The basic data elements for both professional and DTC journal advertising campaigns shall include, if available: report by manufacturer and pharmaceutical product; search by journal ad name; search by date; search by therapeutic class; search by campaign message (e.g., “better than,” “first in new class,” etc.); and includes a picture of the entire ad (with brief summary) with enough resolution to see fine print, and includes dollar expenditures by manufacturer, therapeutic class, and pharmaceutical product. 2) Technical Requirement and Capabilities. The prescription drug promotion data shall be a currently existing, commercially available product that shall provide immediate automated access with the capability of providing national estimates of expenditures by pharmaceutical companies including national estimates of product sampling and promotional expenditures data as well as the content and message of pharmaceutical detailing and advertising campaigns. The data shall be a currently existing, commercially available product that shall provide immediate automated access with the capability of providing both current and historical national-level prescription drug promotion data. Access to the data shall be immediate, direct, desktop and in real-time. Access shall include all upgrades, enhancements, and modifications to software and data. Access shall be via secure Internet or network-based methods and shall be in a multi-user environment. The network-based methods shall not necessitate any additions to the FDA communications infrastructure. Preferred methods for access (in order of preference) are: 1) secure Internet access, and 2) firewall-to-firewall virtual private network (VPN). FDA shall not support modem-based or dial-up access. Additionally, FDA shall not support or maintain Offeror’s equipment or personnel on premises. The NAICS Code is 541990; size standard is $6.5M. Interested small business must provide a capability statement demonstrating their experience, skills and capability to fulfill the Government requirement that is stated above. However, be advised that generic capability statements are not sufficient to evaluate your capability statement effectively. Information submitted must be in sufficient detail to permit the government to determine whether your organization meets the government requirement. This notice is for planning purposes only, and does not constitute a Request for Quotation. This request is not to be construed as a commitment on the part of the Government to award a purchase order or contract, nor does the Government intend to pay for any information submitted as a result of this request. The Government will not reimburse respondents for any cost associated with submission of the information being requested or reimburse expenses incurred to interested parties for responses to this announcement. Interested small business organizations that believe they possess the capabilities necessary to undertake this project should submit information via email copies of their capability statement, addressing the areas above. NO COLLECT CALLS WILL BE ACCEPTED. RESPONDENTS MUST SUBMIT CAPABILITY STATEMENT VIA E-MAIL to Linda Alexander-Giles at linda.alexander-giles@fda.hhs.gov, no later than December 15, 2008 at 3:00 PM Eastern Time for consideration.
- Web Link
-
FedBizOpps Complete View
(https://www.fbo.gov/?s=opportunity&mode=form&id=9ef9a8fc09955d758cf516086439dae0&tab=core&_cview=1)
- Place of Performance
- Address: FDA- Center for Drug Evaluation and Research, 10903 New Hampshire Ave, Silver Spring, Maryland, 20993, United States
- Zip Code: 20993
- Zip Code: 20993
- Record
- SN01700358-W 20081106/081104214739-9ef9a8fc09955d758cf516086439dae0 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |